Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan;
In Vivo. 2022 Sep-Oct;36(5):2365-2370. doi: 10.21873/invivo.12968.
The aim of this study was to evaluate the prognosis of patients with T1N0M0 urothelial carcinoma with squamous differentiation (UCSD) or glandular differentiation (UCGD) because it has not been determined whether these variant histologies behave more aggressively than pure urothelial carcinoma (PUC).
Ninety-nine patients diagnosed with pT1N0M0 bladder cancer and treated conservatively with transurethral resection of bladder tumor at Kanazawa University Hospital between 2007 and 2019 were included in this study. The overall survival, cancer-specific survival (CSS), and recurrence-free survival of the variant histology and PUC groups were evaluated and compared.
The variant histology group had significantly lower overall survival (p=0.006) and CSS (p=0.0095) than the PUC group did. Variant histology was found to be an independent prognostic factor in univariate and multivariate analyses for overall survival and CSS. On the other hand, no significant difference in progression-free survival was observed between the two groups (p=0.439). However, the variant histology group had significantly lower overall survival (p=0.004) and CSS (p=0.004) after progression.
The prognosis for patients with pT1 bladder cancer with UCSD or UCGD treated conservatively with transurethral resection of bladder tumor was poor. Considering the worse prognosis of these patients after stage progression, early radical cystectomy could be recommended.
本研究旨在评估具有鳞状分化(UCSD)或腺体分化(UCGD)的 T1N0M0 尿路上皮癌患者的预后,因为尚未确定这些变异组织学是否比纯尿路上皮癌(PUC)更具侵袭性。
本研究纳入了 2007 年至 2019 年期间在金泽大学医院接受经尿道膀胱肿瘤切除术保守治疗的 99 例 pT1N0M0 膀胱癌患者。评估并比较了变异组织学组和 PUC 组的总生存率、癌症特异性生存率(CSS)和无复发生存率。
变异组织学组的总生存率(p=0.006)和 CSS(p=0.0095)明显低于 PUC 组。在单因素和多因素分析中,变异组织学均是总生存率和 CSS 的独立预后因素。另一方面,两组之间无进展生存率无显著差异(p=0.439)。然而,在进展后,变异组织学组的总生存率(p=0.004)和 CSS(p=0.004)明显降低。
对于接受经尿道膀胱肿瘤切除术保守治疗的 pT1 膀胱癌患者,具有 UCSD 或 UCGD 的患者预后较差。考虑到这些患者在疾病进展后的预后更差,建议早期行根治性膀胱切除术。